KWKimberly Wilkins

Kimberly Wilkins

*This is an algorithmically generated author record based on publicly available information.

Kimberly Wilkins has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea M. McCollum

    U.S. Centers for Disease Control and Prevention

    2 shared publications
  • Crystal M. Gigante

    Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

    2 shared publications
  • Faisal Syed Minhaj

    Centers for Disease Control and Prevention, Atlanta, Georgia (P.A.C., F.S.M., P.J.W., M.M.T., D.L.H., A.A., A.K.R., S.M.O.)

    2 shared publications
  • Whitni Davidson

    Poxvirus and Rabies Branch, Centers for Disease Control and Prevention , Atlanta, Georgia

    2 shared publications
  • Yu Li

    Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

    2 shared publications
  • Agam K. Rao

    National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

    1 shared publication

Latest Publications

  • Six Cases of Borealpox and Evidence of a Zoonotic Source: Alaska, 2020–2023

    by Eric Q Mooring, Julia Rogers, Florence Whitehill, Zachary Werle, Crystal M Gigante, Audrey Matheny, Carrie Conley, Benjamin P Westley, Amber Kunkel, Katherine G Newell, et al.

    Background: Borealpox virus (previously known as Alaskapox virus) is an Orthopoxvirus species first identified in a patient living near Fairbanks, Alaska, in 2015; the source of the patient's infection was unknown. Six additional borealpox cases have been identified through 2023. Methods: We conducted interviews to ascertain travel history and potential exposures for the six patients, trapped small mammals for orthopoxvirus testing, and performed a phylogenetic analysis of viral DNA sequences. Results: Five patients had similar clinical illness, consisting of at least one lesion and, in most cases, lymphadenopathy. One patient with underlying immunosuppression experienced severe illness, hospitalization, and died despite receiving investigational orthopoxvirus therapeutics. One of the patients had a self-reported prior history of smallpox vaccination. None had traveled outside of Alaska, and there was no evidence of person-to-person transmission. Borealpox virus DNA and serologic evidence for past orthopoxvirus infection were detected in multiple small-mammal species. Genetic distance and phylogenetic analyses are compatible with multiple spillover events from animals to humans. Conclusions: Epidemiologic, ecologic, and phylogenetic evidence indicate that borealpox is a zoonotic disease, and current data suggest the reservoir is likely small mammals. Although most infections are mild and self-limiting, immunosuppressed persons may be at risk for severe disease. Further studies are needed to determine the geographic range of borealpox virus in small mammals throughout the Circumpolar North.


  • Top Cited Papers

    Multiple lineages of monkeypox virus detected in the United States, 2021–2022

    by Crystal M. Gigante, Bette Korber, Matthew H. Seabolt, Kimberly Wilkins, Whitni Davidson, Agam K. Rao, Hui Zhao, Todd G. Smith, Christine M. Hughes, Faisal Minhaj, et al.

    Monkeypox is a viral zoonotic disease endemic in Central and West Africa. In May 2022, dozens of non-endemic countries reported hundreds of monkeypox cases, most with no epidemiological link to Africa. We identified two lineages of monkeypox virus (MPXV) among two 2021 and seven 2022 US monkeypox cases: the major 2022 outbreak variant called B.1 and a minor contemporaneously sampled variant called A.2. Analyses of mutations among these two variants revealed an extreme preference for GA-to-AA mutations indicative of human APOBEC3 cytosine deaminase activity among Clade IIb MPXV (previously West African, Nigeria) sampled since 2017. Such mutations were not enriched within other MPXV clades. These findings suggest that APOBEC3 editing may be a recurrent and a dominant driver of MPXV evolution within the current outbreak.